rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The reference standard for amyloid-PET quantification requires structural MRI (sMRI) for preprocessing in both multi-site research studies and clinical trials. Here we describe rPOP (robust PET-Only Processing), a MATLAB-based MRI-free pipeline implementing non-linear warping and differential smoothing of amyloid-PET scans performed with any of the FDA-approved radiotracers (18F-florbetapir/FBP, 18F-florbetaben/FBB or 18F-flutemetamol/FLUTE). Each image undergoes spatial normalization based on weighted PET templates and data-driven differential smoothing, then allowing users to perform their quantification of choice. Prior to normalization, users can choose whether to automatically reset the origin of the image to the center of mass or proceed with the pipeline with the image as it is. We validate rPOP with n = 740 (514 FBP, 182 FBB, 44 FLUTE) amyloid-PET scans from the Imaging Dementia—Evidence for Amyloid Scanning – Brain Health Registry sub-study (IDEAS-BHR) and n = 1,518 scans from the Alzheimer's Disease Neuroimaging Initiative (n = 1,249 FBP, n = 269 FBB), including heterogeneous acquisition and reconstruction protocols. After running rPOP, a standard quantification to extract Standardized Uptake Value ratios and the respective Centiloids conversion was performed. rPOP-based amyloid status (using an independent pathology-based threshold of ≥24.4 Centiloid units) was compared with either local visual reads (IDEAS-BHR, n = 663 with complete valid data and reads available) or with amyloid status derived from an MRI-based PET processing pipeline (ADNI, thresholds of >20/>18 Centiloids for FBP/FBB). Finally, within the ADNI dataset, we tested the linear associations between rPOP- and MRI-based Centiloid values. rPOP achieved accurate warping for N = 2,233/2,258 (98.9%) in the first pass. Of the N = 25 warping failures, 24 were rescued with manual reorientation and origin reset prior to warping. We observed high concordance between rPOP-based amyloid status and both visual reads (IDEAS-BHR, Cohen's k = 0.72 [0.7–0.74], ∼86% concordance) or MRI-pipeline based amyloid status (ADNI, k = 0.88 [0.87–0.89], ∼94% concordance). rPOP- and MRI-pipeline based Centiloids were strongly linearly related (R2:0.95, p<0.001), with this association being significantly modulated by estimated PET resolution (β= -0.016, p<0.001). rPOP provides reliable MRI-free amyloid-PET warping and quantification, leveraging widely available software and only requiring an attenuation-corrected amyloid-PET image as input. The rPOP pipeline enables the comparison and merging of heterogeneous datasets and is publicly available at https://github.com/leoiacca/rPOP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490 · cited 1×
“, cerebellum for AD (Thal et al., 2002)), and of areas in which specific binding would indicate the ongoing disease process (e.”
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728 · cited 2×
“PET quantification may in the future be used to gauge treatment response or manage dose titration and treatment duration, as was done in a recent Phase 2 study of the anti-amyloid antibody donanemab (Mintun et al., 2021).”
The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348 · cited 3×
“We also obtain tracer-specific Centiloid conversion formulas for each of the FDA-approved radioligands, following the process outlined in the Centiloid methods paper (Klunk et al., 2015).”
InfluentialSelf-citationThe first step for neuroimaging data analysis: DICOM to NIfTI conversion
Li, X., Morgan, P. S., Ashburner, J., Smith, J., & Rorden, C. (2016) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2016.03.001 · Cited by 1,073
Imaging the evolution and pathophysiology of Alzheimer disease
Jagust, W. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0067-3 · Cited by 604 · cited 2×
“Positron emission tomography (PET) with specific radioligands can be used to measure brain amyloid plaque accumulation (amyloid-PET) in both clinical practice and research (Jagust, 2018; Villemagne et al., 2018).”
La Joie, R., Ayakta, N., Seeley, W. W., Borys, E., Boxer, A. L., DeCarli, C., Doré, V., Grinberg, L. T., Huang, E., Hwang, J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.09.001 · Cited by 317
Self-citationValidation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach
Initiative, F. T. A. D. N., Royse, S. K., Minhas, D. S., Lopresti, B. J., Murphy, A., Ward, T., Koeppe, R. A., Bullich, S., DeSanti, S., Jagust, W. J., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00836-1 · Cited by 237
Self-citationControversy and Progress in Alzheimer’s Disease — FDA Approval of Aducanumab
Rabinovici, G. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmp2111320 · Cited by 155 · cited 2×
“…may be increasingly important in clincal practice given recent advances in molecular-specific therapies for D. Aducanumab, an amyloid-beta targeting monoclonal antibody, was ecently granted accelerated approval by the FDA for the treatment of CI or mild dementia due to AD ( Rabinovici, 2021 ).”
Self-citation
Cited by
Barthélemy, N. R., Salvadó, G., Schindler, S. E., He, Y., Janelidze, S., Collij, L. E., Saef, B., Henson, R. L., Chen, C. D., Gordon, B. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02869-z · Cited by 448
“Notably, there was very high agreement between quantitative and visual read for Aβ PET status in our cohort (~95%), consistent with previous studies showing very high agreement between visual assessment and Aβ PET quantification 45,51–54 .”
ResultSelf-citationDonanemab: Appropriate use recommendations
Rabinovici, G. D., Selkoe, D. J., Schindler, S. E., Aisen, P., Apostolova, L. G., Atri, A., Greenberg, S. M., Hendrix, S. B., Petersen, R. C., Weiner, M., et al. (2025) · The Journal of Prevention of Alzheimer's Disease · doi:10.1016/j.tjpad.2025.100150 · Cited by 278
Self-citationQuantification of amyloid PET for future clinical use: a state-of-the-art review
Pemberton, H. G., Collij, L. E., Heeman, F., Bollack, A., Shekari, M., Salvadó, G., Alves, I. L., Garcia, D. V., Battle, M., Buckley, C., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05784-y · Cited by 226
“The IDEAS team recently published their PET-only processing pipeline to support the use of standardised quantitative measures in heterogeneous datasets [211].”
Method
Metadata
- Authors
- Iaccarino, L., La Joie, R., Koeppe, R., Siegel, B. A., Hillner, B. E., Gatsonis, C., Whitmer, R. A., Carrillo, M. C., Apgar, C., Camacho, M. R., Nosheny, R., & Rabinovici, G. D.
- Venue
- NeuroImage
- Publisher
- Elsevier BV
- Published
- 2022-02
- Volume
- 246
- Pages
- 118775
- ISSN
- 1053-8119 (ISSN-L)
- OpenAlex
- W4200538449
- Cited by
- 64
- References
- 8
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data. https://app.cochat.ai/papers/10.1016/j.neuroimage.2021.118775
- The paper
- Iaccarino, L., La Joie, R., Koeppe, R., Siegel, B. A., Hillner, B. E., Gatsonis, C., Whitmer, R. A., Carrillo, M. C., Apgar, C., Camacho, M. R., Nosheny, R., & Rabinovici, G. D. (2022). rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data. NeuroImage. https://doi.org/10.1016/j.neuroimage.2021.118775
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.